John S. Kovach, M.D., President, Lixte Biotechnology Holdings, Inc. (LIXT.PK), commented on the study, HCC is the most common cancer worldwide occurring primarily in individuals with underlying hepatitis B infection and is the third leading cause of all cancer-related deaths.